121 results found | searching for "Partnership"

2 3 4 5 6 7 8 9 10 Next Last 
  • Healthcare_medical
  • Innovations in Bariatric Surgery Devices: Improving Patient Outcomes https://bit.ly/3WY6Gz2 The bariatric surgery devices market is valued to reach USD 2.4 billion by 2027 from an estimated USD 1.9 billion in 2022, at a CAGR of 5.4% during the forecast period. The bariatric surgery devices market is driven by the rising obesity cases worldwide and subsequent increase in bariatric surgeries coupled with the growing demand for minimally invasive surgeries. The top players in bariatric surgery devices market are Johnson & Johnson (US), Medtronic plc (Ireland), Intuitive Surgical, Inc. (US), Apollo Endosurgery, Inc. (US), and Olympus Corporation (Japan). These market players have invested in organic strategies such as product launches and regulatory approvals and inorganic growth strategies such as partnerships and acquisitions to maintain their market shares
  • jameshebrew
  • The exosome therapeutics market is projected to grow at an annualized rate of 41%, claims Roots Analysis Driven by the development of novel platforms and advanced technologies along with consistent efforts of the stakeholders in research and development of exosome therapeutics which is set to see some FDA approved therapies in this decade Roots Analysis has announced the addition of “Exosome Therapeutics Market, 2022-2040” report to its list of offerings. With the advancements in technologies developing targeted drug delivery therapies, the researchers are shifting their focus on exosomes as therapeutic drug interventions and drug delivery carriers. The growing interest in exploring exosomes for therapeutic purposes can be attributed to their ability to enter the respective organs, manifesting best results even in a weakened immune system and be stored for longer periods of time, owing to their greater life span. Driven by the ongoing pace of innovation and sufficient financial support from investors, the exosome therapeutics market is anticipated to witness substantial growth in the foreseen future. Key Market Insights Presently, 120+ exosome therapeutics are being evaluated across different phases of development for the treatment of numerous disease indications, including COVID-19 More than 40% clinical candidates are being evaluated in late stages (phase II and above) of clinical development, while 60% of the therapeutic candidates are in preclinical stage of development. More than 80% of the therapy candidates, that are being developed to target a range of disease indications, are allogeneic in nature. More than 60 industry and non-industry players are engaged in the development of exosome therapeutics, globally Asia-Pacific and Rest of the World has emerged as the hub, featuring the presence of approximately 40% developers. The exosomes market is currently dominated by the presence of small firms (47%). Interestingly, 11% of the players are mid-sized, engaged in the development of these novel therapeutics. Till date, more than 4,000 patients have been enrolled in around 55 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased over the last two years. Of the total number of trials, more than 50% are active and still recruiting patients, while close to 20% have already been completed. Grants worth over USD 200 million have been awarded to support the ongoing research efforts More than USD 150 million have been awarded for the support period of less than 4 years to identify and develop novel exosome therapeutics. Further, about 85% grants have been awarded for the purpose of non-small business innovation research and technology transfer, amounting to more than USD 185 million. Close to 50 global events related to exosomes were organized in the last few years Majority of the events related to exosomes were organized in North America (56%). It is worth highlighting that the main agenda of these events was to discuss the developments and challenges associated with exosome-based therapeutics. Partnership activity within this domain has grown at a CAGR of 53%, between 2017 and 2021 Maximum number of partnerships were established in 2020 indicating a recent rise in the interest of players engaged in the field of exosomes therapeutics. It is worth highlighting that the majority of the deals were research agreements, representing over 35% of the total number of partnerships signed. This is followed by development agreements (16%) and licensing agreements (14%). Amount close to USD 550 million has been invested by both private and public investors, across 35 funding instances, since 2017 Companies involved in the development of exosome therapeutics have raised around USD 330 million through venture funding, which represents 40% of the total capital raised between 2017 to 2022. Overall, around 85 investors have actively financed various projects / initiatives in this domain. The market is anticipated to grow at a CAGR of 41.1%, during the period 2029-2040 Owing to the approvals of a number of exosome therapeutic candidates in the coming years, anticipated billion-dollar market is to be divided across various segments. Asia-Pacific (primarily China) is expected to capture more than 70% of the market share by 2040. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/exosome-therapeutics-market/request-sample.html Key Questions Answered  Who are the leading industry and non-industry players engaged in the development of exosome therapies?  Which are the key drugs being developed across early and late stages of development?  What are the key agendas being discussed in various global events / conferences related to exosomes?  What kind of partnership models are commonly adopted by industry stakeholders?  Which are the leading funding institutes / centers supporting the research related to exosome therapies?  Which geographies are the most active in conducting clinical trials related to exosome therapies?  How is the current and future market opportunity, related to exosome therapies likely to be distributed across key market segments? The financial opportunity within the exosome therapeutics market has been analyzed across the following segments:  Type of Therapeutic  Allogeneic Therapy  Autologous Therapy  Target Indication(s)  Degenerative Meniscal Injury  Dystrophic Epidermolysis Bullosa  Fistula Perianal  Retinitis Pigmentosa  Therapeutic Area  Dermatological Disorders  Muscoskeletal Disorders  Ophthalmic Diseases  Rectal Disorders  Route of Administration  Fistula Tract  Intra-articular  Intra-ocular  Geography  North America  Europe  Asia-Pacific and Rest of the World The report features inputs from eminent industry stakeholders, according to whom, exosome therapeutics are increasingly being recognized as novel modulators for different therapeutic purposes. The report includes detailed transcripts of discussions held with the following experts:  Xavier Avat (Chief Business Officer, Capricor Therapeutics)  Patricia C. Freire (R&D and Innovation Manager, Exogenus Therapeutics)  Soonho Song (Chief Business Officer, ILIAS Biologics) The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about drug, such as information on type of therapy and current development status, information on type of therapy (if available), recent developments related to exosome therapeutics and manufacturing capabilities of the players.  Codiak BioSciences  Coya Therapeutics  Curexsys  EV Therapeutics  Evox Therapeutics  SHIFTBIO  AEGLE Therapeutics  AVEM Healthcare  Cellular Biomedicine Group  OBCTCD24  ReNeuron  Stem Cell Medicine For additional details, please visit https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • sakshishah564
  • Shisham Digital offers worldwide audience segmented performance marketing through our own assets and co-marketing partnerships. We have a strong global presence in Singapore, the USA, Dubai, and India with growing network. Visit here - https://www.shishamdigital.com/
  • jameshebrew
  • The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis A number of biopharmaceutical companies are outsourcing their biologics fill / finish operations, thereby, prompting stakeholders engaged in this domain to undertake several expansion initiatives, to cater to the needs of clients around the globe. Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings. Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/256/request-sample.html Key Market Insights More than 175 service providers claim to offer services for biologic fill / finish operations The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide. Several partnerships have been established in the biologics fill / finish services domain, since 2013 Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines. Over 170 expansions have been reported in biologics fill / finish services domain, since 2013 More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations. The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees). The demand for biologics fill / finish services is expected to grow at an annualized rate of 14% Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region. Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035 In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/biologics-fill-finish-services-market/256.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • jameshebrew
  • The mRNA synthesis and manufacturing market is projected to be worth USD 1.5 billion by 2035, claims Roots Analysis Given the current technical and operational challenges associated with the manufacturing of mRNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the mRNA synthesis and contract manufacturing service providers. Roots Analysis has announced the addition of “mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022–2035” report to its list of offerings. Owing to the recent success and growing pipeline of mRNA-based products in the market, mRNA, as a therapeutic agent, has gained significant traction from the medical community. However, due to challenges, such as high capital requirement, stringent regulations and lack of technical expertise, outsourcing has become a preferred business model and CMOs are upgrading their existing capabilities and service portfolios to meet the increased demand for mRNA-based products. Key Market Insights Presently, 30+ companies claim to offer custom synthesis services for mRNA, globally. Majority of the service providers are mid-sized players (44%), followed by small (35%), large (12%) and very large players (9%). Additionally, more than 25% of the stakeholders were established post 2010. It is also worth mentioning that over 50% of the total players are based in North America, specifically in the US. More than 40 companies, across the globe, claim to provide contract manufacturing and fill / finish services for mRNA vaccines / therapeutics. Of the aforementioned players, nearly 85% of the contract manufacturing service providers are based in North America and Europe. Notably, more than 50% of the total players engaged in this space offer services for drug substance (APIs) manufacturing. Currently, more than 95 mRNA synthesis kits are available in the market. Close to 70% of the mRNA synthesis kits contain capping enzymes; of these, 96% use T7 RNA polymerase enzyme mix for the synthesis of modified mRNAs. It is worth highlighting that majority (54%) of the kit developers are small players. More than 170 clinical trials have been registered for the evaluation of mRNA-based therapeutics / vaccines, worldwide. The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 44%, during the period 2017-2022. Of the total number of trials registered, close to 22% have already been completed, while 46% of the studies are actively recruiting participants. Partnership activity within this domain has grown at a CAGR of 60%, between 2019 and 2022. Nearly 34% of the deals were inked in 2021. Majority of the instances captured in the report were manufacturing agreements, representing 22% of the total partnerships. Further, most of the intercontinental deals have been inked by players based in North America. North America and Europe are anticipated to capture close to 65% of the global market share, by 2035. The market in Asia Pacific is likely to grow at the highest CAGR during the period 2022-2035. In terms of type of product, drug substance (APIs) is expected to occupy a larger share (70%) of the overall mRNA synthesis and manufacturing service market in 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market/request-sample.html Key Questions Answered  What are the factors driving mRNA synthesis and manufacturing market?  How many players are providing services for custom synthesis of mRNAs?  How many players are offering mRNA contract manufacturing services for commercial purposes?  How many kits are available in the market for the synthesis of mRNA?  Which geographical segment has the highest growth rate in mRNA synthesis and manufacturing market?  Which segment, in terms of type of product, accounts for the largest mRNA synthesis and manufacturing market share?  What is the partnership and collaboration trends in mRNA synthesis and manufacturing domain?  Who are the key players in mRNA synthesis and manufacturing market? The financial opportunity within the mRNA synthesis and manufacturing service market has been analysed across the following segments:  Type of Product  Drug substances (APIs)  Drug products (FDFs)  Application Area  mRNA-based vaccines  mRNA-based therapeutics  Therapeutic Area  Infectious diseases  Oncological disorders  Other diseases  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa  Rest of the World The research also includes detailed profiles of the key players (listed below) engaged in mRNA synthesis and manufacturing domain; each profile features a brief overview of the company, details related to its service portfolio (for mRNA synthesis and contract manufacturing service providers) / product portfolio (mRNA synthesis kit providers), recent developments and an informed future outlook.  Aldevron  APExBIO  Biomay  Bio-Synthesis  CELLSCRIPT  eTheRNA  Eurogentec  Jena Biosciences  New England Biolabs  Thermo Fisher Scientific  TriLink BioTechnologies For additional details, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • jameshebrew
  • THE GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET FOR HEALTHCARE TO GROW AT AN ANNUALIZED RATE OF ~14%, TILL 2035 The global demand for biologics currently holds the largest share in the non-viral drug delivery domain and is expected to show the similar trend in the coming years. Further, the nanoparticle and extracellular vesicles emerged as the star as per the BCG matrix during our research. In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry. It is also interesting to note that the polymer has a low growth rate but a higher market share. Hence, it is considered as the cash cow in the current time. The ongoing research for various types of technological modifications is expected to lead to the development of newer generation of non-viral drug delivery systems that are anticipated to hold a significant share in the future market. Over the past few years, players engaged in the domain of non-viral drug delivery have signed various partnerships aiming in efficient intracellular delivery of drugs. During our research, we observed that majority of the partnership deals (42%) were technology licensing deals followed by technology evaluation agreement (20%). Additionally, intracellular drug delivery systems market has witnessed seven instances of acquisitions and mergers in the given time period. This trend reflects that companies are continuously striving to expand their existing service offerings. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market/request-sample.html The global demand for biologics currently holds the largest share in the non-viral drug delivery domain. However, the demand for small molecule in the long term is anticipated to increase as the new advances the medical field would soon allow the intracellular delivery of drugs orally. For additional details, please visit https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • jameshebrew
  • Given the potential of digital twins to replicate the physical world in a digital layout, as well as their ability to provide real-time outputs, while gathering constant inputs from the real-world, such products have generated significant interest within the healthcare domain Roots Analysis has announced the addition of “Digital Twins Market, 2022-2035” report to its list of offerings. Since the first application of the digital twin concept for manufacturing in 2002, it has emerged as a crucial component for companies to achieve higher efficiency in their production processes. According to the US-based Digital Twin Consortium, digital twins hold the potential to reduce clinical trial expenditure, turnaround times, staffing expenses and plan medical intervention. Digital twin technology companies are currently engaged in the development of products which are intended for numerous applications, such as asset / process management, personalized treatment and surgical planning. Key Market Insights Over 35 digital twins are presently available in this market space More than 60% of the digital twins offered by industry players are body part twins; these products are primarily intended for asset / process management, personalized treatment and surgical planning. Further, majority of the products that are currently under development are focused on the treatment of indications, such as cardiovascular disorders, metabolic disorders, and neurological disorders. More than 30 players currently claim to be engaged in the digital twin domain Majority of the players engaged in this industry are small firms (11-50 employees, 37%), followed by very large players (10,000+ employees, 22%), large players (501-10,000 employees, 19%), mid-sized players (51-500 employees, 13%) and very small companies (2-10 employees, 9%). Additionally, nearly 70% of the developers are based in Europe, followed by those based in North America (28%). Partnership activity for digital twins witnessed a CAGR of over 15%, in the past three years More than 50% of the partnerships have been signed since January 2020; of these, four partnerships were inked in the year 2022. Technology integration agreements have emerged as the most popular (30%) type of partnership model in the market, followed by technology utilization agreements (23%). Nearly USD 6 billion invested across the globe to advance digital twins focused initiatives A steady increase has been observed in funding activity since 2020, with the maximum number of instances (10) being reported in the year 2021. In fact, more than 90% of the total investment (in terms of the amount invested) was made in the last two years alone (2021- 2022). Of the amount raised in 2022, about USD 4.2 billion was contributed by the IPO of Babylon. Berkus start-up valuation analysis has been performed to evaluate start-ups in this domain The framework enables valuation of start-ups, based on several key success / risk factors . The key factors are assigned monetary values based on the qualities / risks possessed by a particular player. At the end, all valuations were added to calculate the final valuation of the company. Players based in North America are anticipated to capture nearly 30% of the market share by 2035 The overall digital twin market is expected to be primarily driven by the growing interest towards automation and prognostic systems. The estimates in our report suggest that digital twins intended to treat cardiovascular disorders are expected to hold 32% share of the market in 2035. It is interesting to mention that market for digital twins intended to serve pharmaceutical companies and medical device manufacturers, collectively, hold over 60% of the market share in 2035. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/digital-twins-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of digital twins for the healthcare domain?  Which type of digital twin is most commonly offered by developers engaged in this market space?  What is the relative competitiveness of different players engaged in the digital twins domain?  What is the likely valuation of start-ups involved in the development of digital twins for the healthcare sector?  What is the present and likely future demand for digital twins in the overall healthcare sector?  What are the anticipated future trends related to digital twins in the healthcare domain?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the digital twins market in the healthcare domain has been analyzed across the following segments:  Therapeutic Area  Cardiovascular Disorders  Metabolic Disorders  Orthopedic Disorders  Other Disorders  Type of Digital Twin  Process Twins  System Twins  Whole Body Twins  Body Part Twins  Area of Application  Asset / Process Management  Personalized Treatment  Surgical Planning  Diagnosis  Other Applications  End Users  Pharmaceutical Companies  Medical Device Manufacturers  Healthcare Providers  Patients  Other End Users  Key Geographical Regions  North America  Europe  Asia  Latin America  Middle East and North Africa  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.  Babylon  ExactCure  ImmersiveTouch  Navv Systems  ThoughtWire  Unlearn.AI For additional details, please visit https://www.rootsanalysis.com/reports/digital-twins-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Flow Cytometry Service Market, 2022-2035 2. Gene Editing beyond CRISPR Market, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact Information Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com [more]
  • Healthcare_medical
  • Healthcare Analytical Testing Services Market Current and Future Industry Trends, 2022 - 2027 https://bit.ly/3IObJPk The healthcare analytical testing services market is projected to reach USD 11.1 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 11.4% during the forecast period. Growth in the market is driven by the growing production and development of pharmaceuticals, biopharmaceuticals, and biologics, as well as the increasing number of clinical trials. The market is competitive and less fragmented. At the top with a large number of leading market players based in developed countries or serve specific end-users or regions rather than offering all services enlisted under healthcare analytical testing. Prominent players in the healthcare analytical testing services market include Eurofins Scientific (Luxembourg), LabCorp (US), SGS (Switzerland), Charles River Laboratories (US), and WuXi AppTec (China). Companies in the healthcare analytical testing services market have adopted strategies such as partnerships, agreements, acquisitions, service launches as well as expansions to enhance their presence in the healthcare analytical testing services market. [more]
  • jameshebrew
  • The smart pharmaceutical and healthcare labels market is anticipated to grow at a CAGR of 16%, till 2035, claims Roots Analysis In order to overcome the limitations and challenges related to counterfeit drugs, researchers and industry stakeholders are gradually adopting smart pharmaceutical and healthcare labels, which offer multiple benefits over conventional labels. Roots Analysis has announced the addition of “Smart Pharmaceutical and Healthcare Labels Market, 2022-2035” report to its list of offerings. A smart label comprises of printed information, a bar code identifier and a small transponder. This transponder contains a processing chip and an antenna that allows physical objects to communicate with the tag reader (for instance, RFID reader). Smart labels offer several benefits, such as tracing and tracking products in a supply chain, tamper proofing, as well as discouraging counterfeiters from packaging fake drugs. In this context, it is worth mentioning that smart labelling technology can potentially save USD 0.8 - 1.5 million per year, per company, through their applications in inventory management. Key Market Insights More than 90 companies claim to offer smart pharmaceutical and healthcare labels, globally This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (less than 50 employees) players, which collectively represent more than 75% of the total smart label providers in pharmaceutical and healthcare sectors. Further, ~20% of firms were established post-2010. 400+ patents related to smart pharmaceutical and healthcare labels were filed / granted, since 2015 Based on intellectual property distribution across the world, R&D activity related to smart pharmaceutical and healthcare labels is largely concentrated in North America (over 65%), followed by Europe (10%). In addition, most of the patents have been granted patent (55%), followed by patent applications (44%). Partnership activity in this domain has increased at a significant pace, between 2018 and 2022 The recent partnerships trend in this market indicates the growing interest of industry stakeholders. It is worth highlighting that majority of the deals were service alliances, representing around 41% of the total number of partnerships signed in the given time period. North America and Europe are anticipated to capture over 65% of the market share by 2035 The markets in Asia-Pacific and Latin America are anticipated to grow at a relatively faster pace. In the long-term, the aforementioned regions are expected to collectively represent 33% of the total market share. In addition, RFID based smart labels are likely to capture more than 75% of the market share in 2035. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/smart-labels-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of smart pharmaceutical and healthcare labels?  What is the relative competitiveness of different smart pharmaceutical and healthcare labels providers?  Which types of partnership models are most commonly being adopted by stakeholders engaged in this domain?  What are the key strategies that can be implemented by emerging players / start-ups to enter the highly competitive market for smart labels for the healthcare sector?  Which companies are actively filing patents to drive innovation in the field of smart pharmaceutical and healthcare labels?  What are the key challenges within the smart pharmaceutical and healthcare labels market?  What is the current / likely future market size of smart pharmaceutical and healthcare labels? The financial opportunity within the smart pharmaceutical and healthcare labels market has been analyzed across the following segments:  Type of Technology  RFID  NFC  Other Technologies  Type of packaging  Primary Packaging  Secondary Packaging  Type of Primary Packaging  Vials  Syringes  Cartridges  Ampoules  Bottles  Blister Packs  Type of Secondary Packaging  Boxes  Cartons  Pouches  Key Geographical Regions  North America  Europe  Asia-Pacific  MENA  Latin America The report includes detailed profiles of key players (listed below) engaged in providing smart pharmaceutical and healthcare labels; each profile features an overview of the developer, details related to smart labels focused product portfolio, recent developments and an informed future outlook:  CCL Industries  Schreiner  Datalogic  Tadbik  SATO  Invengo  Intellhydro Technology  RFiD Discovery  ID Tech Solutions For additional details, please visit https://www.rootsanalysis.com/reports/smart-labels-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Pharmaceutical Secondary Packaging Market: Industry Trends and Global Forecast, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com [more]
  • jasoncohen91
  • Jason Cohen Pittsburgh Website: https://somerspoint.com/2022/01/27/jason-cohen-nexus-real-estate-shares-tips-choosing-first-investment-property/ Address: 2275 Swallow Hill Rd, Pittsburgh, PA 15220 Phone: (412) 455-5600 Jason Cohen of Nexus Real Estate in Pittsburgh, PA is a real estate reclamation expert who has developed a portfolio of dozens of rental assets including commercial and residential properties. Jason Cohen is the founder of Nexus Real Estate and also Jason Cohen Pittsburgh, which is a resource for clients in the real estate market. Mr. Cohen can be contacted for partnership opportunities through the Jason Cohen Nexus website. #Real Estate #Jason Cohen Nexus Real Estate
2 3 4 5 6 7 8 9 10 Next Last